Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context

Antonio González-Martín; Ursula A. Matulonis; Jacob Korach; Mansoor R. Mirza; Kathleen N. Moore; Xiaohua Wu; Whitney York; Divya Gupta; Stanislav Lechpammer; Bradley J. Monk

doi:10.2217/fon-2022-0206

Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context

Antonio González-Martín, Ursula A. Matulonis, Jacob Korach, Mansoor R. Mirza, Kathleen N. Moore, Xiaohua Wu, Whitney York, Divya Gupta, Stanislav Lechpammer, Bradley J. Monk

Obstetrics & Gynecology

Research output: Contribution to journal › Review article › peer-review

Abstract

We reviewed clinical data for niraparib monotherapy in BRCA-mutated (BRCAm) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCAm versus non-BRCAm cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCAm OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).

Original language	English
Pages (from-to)	2505-2536
Number of pages	32
Journal	Future Oncology
Volume	18
Issue number	23
DOIs	https://doi.org/10.2217/fon-2022-0206
State	Published - Jul 2022

Keywords

BRCA mutation
Clinical studies as topic
Efficacy
Niraparib
Ovarian cancer
Quality-of-life
Safety

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2022-0206

Cite this

@article{7867878c07364afa8c9b5f5de15c63ee,

title = "Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context",

abstract = "We reviewed clinical data for niraparib monotherapy in BRCA-mutated (BRCAm) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCAm versus non-BRCAm cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCAm OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).",

keywords = "BRCA mutation, Clinical studies as topic, Efficacy, Niraparib, Ovarian cancer, Quality-of-life, Safety",

author = "Antonio Gonz{\'a}lez-Mart{\'i}n and Matulonis, {Ursula A.} and Jacob Korach and Mirza, {Mansoor R.} and Moore, {Kathleen N.} and Xiaohua Wu and Whitney York and Divya Gupta and Stanislav Lechpammer and Monk, {Bradley J.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors.",

year = "2022",

month = jul,

doi = "10.2217/fon-2022-0206",

language = "אנגלית",

volume = "18",

pages = "2505--2536",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "23",

}

TY - JOUR

T1 - Niraparib treatment for patients with BRCA-mutated ovarian cancer

T2 - Review of clinical data and therapeutic context

AU - González-Martín, Antonio

AU - Matulonis, Ursula A.

AU - Korach, Jacob

AU - Mirza, Mansoor R.

AU - Moore, Kathleen N.

AU - Wu, Xiaohua

AU - York, Whitney

AU - Gupta, Divya

AU - Lechpammer, Stanislav

AU - Monk, Bradley J.

PY - 2022/7

Y1 - 2022/7

N2 - We reviewed clinical data for niraparib monotherapy in BRCA-mutated (BRCAm) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCAm versus non-BRCAm cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCAm OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).

AB - We reviewed clinical data for niraparib monotherapy in BRCA-mutated (BRCAm) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73-78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCAm versus non-BRCAm cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCAm OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).

KW - BRCA mutation

KW - Clinical studies as topic

KW - Efficacy

KW - Niraparib

KW - Ovarian cancer

KW - Quality-of-life

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85134159373&partnerID=8YFLogxK

U2 - 10.2217/fon-2022-0206

DO - 10.2217/fon-2022-0206

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 35791804

AN - SCOPUS:85134159373

SN - 1479-6694

VL - 18

SP - 2505

EP - 2536

JO - Future Oncology

JF - Future Oncology

IS - 23

ER -

Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this